Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AnaptysBio, Inc. (ANAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on immunology therapeutics, AnaptysBio uses these filings to report material events related to its clinical programs, collaborations, capital allocation decisions and strategic plans.
Recent Form 8-K filings describe several categories of information. Some filings report results of operations and financial condition, where AnaptysBio furnishes press releases detailing quarterly financial results and business updates. Others fall under Regulation FD disclosure, such as filings that provide updated corporate investor presentations or slide decks used in conference calls discussing programs like ANB033 or the company’s broader pipeline.
Additional 8-Ks highlight other events, including board authorization of amendments to the company’s stock repurchase plan and the board’s approval of plans to explore separating AnaptysBio’s business into two independent, publicly traded companies by the end of 2026. Filings also cover the company’s Verified Complaint in Delaware Chancery Court against Tesaro and GSK concerning the Collaboration and Exclusive License Agreement for Jemperli, as well as references to Tesaro and GSK’s complaint against AnaptysBio.
For investors analyzing ANAB, these filings help clarify how AnaptysBio reports litigation developments, collaboration terms, royalty monetization arrangements, and major strategic decisions. On Stock Titan, SEC documents are paired with AI-powered summaries that explain the main points of each filing in plain language, highlight notable items such as litigation updates or changes to repurchase plans, and make it easier to scan multiple 8-Ks and other forms without reading every line of legal text.
AnaptysBio, Inc. reported insider equity activity by its Chief Financial Officer, Dennis Mulroy. On January 7, 2026, 6,700 restricted stock units (RSUs) were settled into an equal number of common shares for no cash consideration, increasing his directly held common stock to 24,367 shares. The RSU award vests in 25% increments annually starting January 7, 2026, subject to continued service.
On January 8, 2026, he sold 2,515 common shares at $44.71 per share to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, he directly held 21,852 common shares and 20,100 RSUs.
AnaptysBio (symbol ANAB) disclosed a planned insider sale of common stock under Rule 144. The notice covers 2,515 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 113,703.15. These shares come from restricted stock units acquired from the issuer on 01/08/2026, with cash as the form of payment.
The filing also lists recent sales by Dennis Mulroy over the prior three months. These include 1,908 shares sold on 01/07/2026 for 83,780.28, 3,363 shares on 01/05/2026 for 1,511,166.85, 10,000 shares on 12/22/2025 for 500,000, and 15,725 shares on 12/16/2025 for 705,333.1. The Rule 144 representation confirms the seller states they are not aware of undisclosed material adverse information about the issuer.
AnaptysBio chief legal officer Eric Loumeau reported RSU vesting and a related tax sale of shares. On January 7, 2026, 5,888 restricted stock units were converted into the same number of shares of AnaptysBio common stock at an exercise price of $0, reflecting that each RSU settles into one share for no cash consideration. After this transaction, Loumeau held 15,045 shares of common stock directly.
On January 8, 2026, he sold 2,210 shares of common stock at a price of $44.71 per share. The filing explains that this sale was executed solely to cover tax withholding obligations arising from the RSU vesting through a “sell to cover” transaction and was not a discretionary sale. Following the sale, Loumeau directly owned 12,835 shares of common stock and 17,662 RSUs that continue to vest in 25% annual increments starting January 7, 2026, contingent on continued service.
A holder of the issuer’s common stock has filed a Rule 144 notice to sell 2,210 shares through Morgan Stanley Smith Barney, with an aggregate market value of $99,914.10. The filing lists 27,688,470 shares of common stock outstanding and targets an approximate sale date of 01/08/2026 on the NASDAQ market.
The 2,210 shares were acquired on 01/08/2026 as restricted stock units from the issuer, paid for in cash. Over the prior three months, the seller, identified as Eric J. Loumeau, reported multiple sales of the issuer’s common stock, including several transactions of 10,000 shares in December 2025 and additional sales in January 2026, each with disclosed gross proceeds.
AnaptysBio President and CEO Daniel Faga, who is also a director, reported the vesting of 26,838 restricted stock units (RSUs) on January 7, 2026. Each RSU converts into one share of common stock for no cash cost, increasing his directly held common shares to 493,625 and leaving 80,512 RSUs outstanding.
On January 8, 2026, Faga reported selling 14,281 shares of common stock at $44.71 per share. According to the disclosure, this sale was made solely to cover tax withholding obligations arising from the RSU vesting through a “sell to cover” transaction, and was not a discretionary trade.
Daniel Faga filed a Rule 144 notice to sell 14,281 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/08/2026, with an aggregate market value of 645,644.01 and 27,688,470 shares outstanding.
The shares to be sold were acquired on 01/08/2026 as restricted stock units from the issuer and paid for in cash. The filing also reports earlier sales over the prior three months, including 9,202 shares sold on 01/07/2026 for gross proceeds of 404,059.82 and 15,309 shares sold on 01/05/2026 for gross proceeds of 688,139.55.
AnaptysBio, Inc. filed a current report to highlight preliminary year-end liquidity it plans to share at the 2026 J.P. Morgan Healthcare Conference. The company expects to report that it had cash, cash equivalents and investments of approximately $310 million as of December 31, 2025.
The figure is described as preliminary and unaudited, and may change once normal year-end closing procedures and the independent audit are completed. AnaptysBio notes that its audited financial statements for the year ended December 31, 2025 are not yet available and that additional information will be needed for a full picture of its financial position and results. The conference presentation containing these details is being furnished as an exhibit and is explicitly not deemed filed for liability purposes under the securities laws.
AnaptysBio, Inc.’s chief legal officer Eric J. Loumeau reported equity award activity and related share sales. On January 6, 2026, 5,545 restricted stock units (RSUs) were settled into the same number of common shares for no cash consideration, and he received a new grant of 17,100 RSUs plus a stock option for 23,200 shares with a $43.91 exercise price.
On January 7, 2026, he reported several sales of common stock at weighted average prices around the mid‑$40s per share, including blocks such as 2,017 shares at $45.11 and 5,281 shares at $45.3839. Footnotes state that some shares were sold to cover tax withholding on RSU vesting and that the transactions were executed under a Rule 10b5‑1 trading plan. Following these transactions, he directly held 9,157 common shares.
ANAB filed a Form 144 notice for a planned insider stock sale. The filing shows a planned sale of 2,017 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of $88,566.47. The shares relate to restricted stock units acquired from the issuer on January 7, 2026 and paid for in cash. The filing lists 27,688,470 shares of the issuer’s common stock outstanding.
The notice also reports prior transactions by Eric J. Loumeau over the past three months, including sales such as 12,500 shares on December 16, 2025 for $560,800.25 and 10,000 shares on December 17, 2025 for $460,000. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
AnaptysBio, Inc. Chief Medical Officer Paul F. Lizzul reported multiple equity transactions. On January 6, 2026, 6,145 restricted stock units (RSUs) converted into the same number of common shares for no cash cost, and his common stock holdings became 39,448 shares. That day he also received 21,400 new RSUs and a stock option for 29,000 shares.
The new RSUs vest 25% per year starting January 6, 2027, while the option vests 25% on January 6, 2027 and then monthly in equal installments, all contingent on continued service. On January 7, 2026, he sold 2,235 common shares at $45.11 solely to cover tax withholding from the RSU vesting, leaving 37,213 common shares owned directly.